COMMUNIQUÉS West-GlobeNewswire

BrainsWay Targets Expansion of its Total Addressable Market through a Strategic Investment in Neuromodulation Systems Developer, Neurolief Ltd.
21/08/2025
This investment marks BrainsWay’s entrance into the market for mental health therapies that can be administered outside of a clinic, including at home Neurolief’s breakthrough Proliv ™ Rx device is pending Premarket [...]
InflaRx Announces Participation in September Investor Conferences
21/08/2025
JENA, Germany, Aug. 21, 2025 (GLOBE NEWSWIRE) -- InflaRx N.V. (Nasdaq: IFRX), a biopharmaceutical company pioneering anti-inflammatory therapeutics by targeting the complement system, today announced it will participate [...]
Pyxis Oncology to Participate in September Investor and Industry Conferences
21/08/2025
BOSTON, Aug. 21, 2025 (GLOBE NEWSWIRE) -- Pyxis Oncology, Inc. (Nasdaq: PYXS), a clinical-stage company developing antibody-drug conjugate (ADC) therapeutics for difficult-to-treat cancers, today announced that Lara S. [...]
Novonesis delivered 9% organic sales growth in H1 and full-year outlook range narrowed to 6-8%
21/08/2025
COPENHAGEN, Denmark – August 21, 2025. Novonesis delivered 9% organic sales growth in H1 and full-year outlook range narrowed to 6-8%. Ester Baiget, President & CEO: “I’m very pleased with 9% organic sales growth in [...]
Advanz Pharma and Alvotech receive European approval for Mynzepli®, Biosimilar to Eylea®
21/08/2025
Mynzepli ® (aflibercept) is approved in all European Economic Area member countries for the treatment of various retinal diseases including neovascular (wet) age-related macular degeneration (AMD) Approval is based on [...]
Advanz Pharma and Alvotech receive European approval for Mynzepli®, Biosimilar to Eylea®
21/08/2025
Mynzepli® (aflibercept) is approved in all European Economic Area member countries for the treatment of various retinal diseases including neovascular (wet) age-related macular degeneration (AMD) Approval is based on [...]
Invivyd Announces Pricing of $50 Million Public Offering of Common Stock and Pre-Funded Warrants
21/08/2025
WALTHAM, Mass., Aug. 20, 2025 (GLOBE NEWSWIRE) -- Invivyd, Inc. (Invivyd) (Nasdaq: IVVD) today announced the pricing of an underwritten public offering of 74,811,404 shares of its common stock at an offering price of $0 [...]
Interim Report Q2 2025: Commercial and operational agility drove market share gains and 46% EBITA growth
21/08/2025
Highlights The Hearing division delivered 8% organic revenue growth driven by broad-based market share gains of ReSound Vivia across global markets growing below structural trends. The strong growth led to 12% growth in [...]
Herantis Pharma releases 1H 2025 report today
21/08/2025
Espoo, Finland, 21 August 2025: Herantis Pharma Plc ("Herantis"), a clinical-stage company developing disease-modifying therapies to stop Parkinson’s disease, releases today the Company’s 1H 2025 report. The full report [...]
Nicox annonce des résultats positifs pour NCX 470 dans l’étude de Phase 3 Denali chez des patients atteints de glaucome
21/08/2025
Communiqué de presse Nicox annonce des résultats positifs pour NCX 470 dans l’étude de Phase 3 Denali chez des patients atteints de glaucome L’atteinte du critère principal dans les deux études Denali et Mont Blanc, la [...]
Nicox Announces Positive Results from the NCX 470 Phase 3 Denali Trial in Glaucoma Patients
21/08/2025
Press Release Nicox Announces Positive Results from the NCX 470 Phase 3 Denali Trial in Glaucoma Patients Achieving the primary endpoint in both Denali and the first NCX 470 Phase 3 trial, Mont Blanc, meets efficacy [...]
Six-month interim report (Q2) 2025 (unaudited)
21/08/2025
ALK delivers 12% organic revenue growth with operating profit up 41% in Q2 Q2 results exceeded expectations, driven by an improved momentum for tablets and adrenaline autoinjectors. Sales in Europe were ahead of plan, [...]
Interim report H1 2025
21/08/2025
9% organic sales growth in H1 and FY outlook range narrowed to 6-8% Ester Baiget, President & CEO: “I’m very pleased with 9% organic sales growth in the first half of the year. Demand for our biosolutions is strong [...]
Telix 2025 Half-Year Results: Strong commercial performance enables investment for long-term growth
21/08/2025
MELBOURNE, Australia and INDIANAPOLIS, Aug. 21, 2025 (GLOBE NEWSWIRE) -- Telix Pharmaceuticals Limited (ASX: TLX, NASDAQ: TLX, "Telix") today announces its financial results for the half-year ended 30 June 2025. All [...]
Latest breakthrough in Type 1 diabetes treatment: Chinese medical team enables 24 patients to discontinue insulin use
21/08/2025
SHENZHEN, China, Aug. 20, 2025 (GLOBE NEWSWIRE) -- Recently, Professor An Chiying and her medical team at Shenzhen Hengsheng Hospital, China, announced a groundbreaking achievement: since June 2024, they have [...]
NurExone Biologic Announces Preclinical Evidence of Structural Repair in Injured Spinal Cord Tissue following ExoPTEN Treatment
20/08/2025
C$0.78 Million Private Placement Successfully Closed TORONTO and HAIFA, Israel, Aug. 20, 2025 (GLOBE NEWSWIRE) -- NurExone Biologic Inc. (TSXV: NRX) (OTCQB: NRXBF) (FSE: J90) (“ NurExone ” or the “ Company ”) is pleased [...]
Sana Biotechnology Announces Closing of Full Exercise of Underwriters’ Option to Purchase Additional Shares
20/08/2025
SEATTLE, Aug. 20, 2025 (GLOBE NEWSWIRE) -- Sana Biotechnology, Inc. (Nasdaq: SANA) (“Sana”), a company focused on changing the possible for patients through engineered cells, today announced that it has closed the sale [...]
Outset Medical to Present at the 23rd Annual Morgan Stanley Global Healthcare Conference
20/08/2025
SAN JOSE, Calif., Aug. 20, 2025 (GLOBE NEWSWIRE) -- Outset Medical, Inc. (Nasdaq: OM) (“Outset”), a medical technology company pioneering a first-of-its-kind technology to reduce the cost and complexity of dialysis, [...]
Olema Oncology to Participate in Upcoming Investor Conferences
20/08/2025
SAN FRANCISCO, Aug. 20, 2025 (GLOBE NEWSWIRE) -- Olema Pharmaceuticals, Inc. (“Olema”, or “Olema Oncology”, Nasdaq: OLMA), a clinical-stage biopharmaceutical company focused on the discovery, development, and [...]

Pages